B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity
Sci Rep, 2016;6(0):29699.
Species: Human
Sample Type: Whole Cells
Application: Flow
A novel population of human CD56+ human leucocyte antigen D-related (HLA-DR+) colonic lamina propria cells is associated with inflammation in ulcerative colitis.
Authors: Ng SC, Plamondon S, Al-Hassi HO, English N, Gellatly N, Kamm MA, Knight SC, Stagg AJ
Clin. Exp. Immunol., 2009;158(2):205-18.
Species: Human
Sample Type: Whole Cells
Application: Flow

Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is essential for the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22-28 kDa phosphorylated and variably glycosylated molecule (1-4). Mature human IL-6 is 183 amino acids (aa) in length and shares 41% aa sequence identity with mouse and rat IL-6 (5). Alternate splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (6-9). Human IL-6 is equally active on mouse and rat cells (10). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (11). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (12). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans-signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R (3). Trans‑signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans-signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 13).

1. Van Snick, J. (1990) Annu. Rev. Immunol. 8:253.
2. Hodge, D.R. et al. (2005) Eur. J. Cancer 41:2502.
3. Jones, S.A. (2005) J. Immunol. 175:3468.
4. Rose-John, S. et al. (2006) J. Leukoc. Biol. 80:227.
5. Hirano, T. et al. (1986) Nature 324:73.
6. Alberti, L. et al. (2005) Cancer Res. 65:2.
7. Kestler, D.P. et al. (1995) Blood 86:4559.
8. Kestler, D.P. et al. (1999) Am. J. Hematol. 61:169.
9. Bihl, M.P. et al. (2002) Am. J. Respir. Cell Mol. Biol. 27:48.
10. Chiu, C.P. et al. (1988) Proc. Natl. Acad. Sci. USA 85:7099.
11. Murakami, M. et al. (1993) Science 260:1808.
12. Muller-Newen, G. (2003) Sci. STKE 2003:PE40.
13. Mitsuyama, K. et al. (2006) Clin. Exp. Immunol. 143:125.